Nektar Therapeutics (NKTR) CEO Howard Robin Sells $612K of Stock
NKTR's CEO Howard Robin sold 10,000 shares in a planned transaction.
Reviewed by automated data checks against the source filing. How we make and check alerts
Howard Robin, President & CEO at Nektar Therapeutics ($NKTR), sold 10,000 shares at an average price of $61.19, worth about $611,880, on June 17, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $NKTR is up 6.4% after 1 week, up 12.1% after 1 month and down 41.3% to date (from the $60.92 close on Jun 17, 2026).
NKTR
Nektar Therapeutics
Key Points
- Howard Robin, President & CEO of NKTR, sold 10,000 shares on June 17, 2026, for about $611,880.
- NKTR shares traded near $60.92 with recent insider transactions by Howard Robin and Jonathan Zalevsky.
- Analysts like Piper Sandler and Citigroup maintain 'buy' ratings with targets up to $192.
Get $NKTR trade alerts by text
We text you when insiders, Congress or big funds trade $NKTR. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Nektar Therapeutics alert may contain errors. Disclosures
On June 17, 2026, Howard Robin, the President and CEO of NKTR, sold 10,000 shares in a planned transaction. The shares were sold at an average price of $61.19, resulting in a total transaction value of approximately $611,880. This sale was part of a scheduled plan.
Insider Buying and Selling at Nektar Therapeutics
Howard Robin has been actively selling shares over the past few months. On June 16, he sold another 10,000 shares at $60.32 each. Earlier, on May 19, he sold 444 shares at $65.51, and on February 18, he sold 423 shares at $73. Jonathan Zalevsky, the Chief R&D Officer, also sold shares, including 5,538 shares on June 15 at $60.71.
Other Institutional Activity in NKTR
Several major funds have adjusted their positions in NKTR. FMR LLC dramatically increased its holdings by 4,202,059 shares, ending with 4,303,188 shares valued at about $309.6 million. BVF INC/IL added 1,000,000 shares, bringing its total to 2,559,595 shares worth approximately $184.2 million. Two Seas Capital LP increased its stake by 1,213,993 shares to a total of 1,959,178 shares valued at around $141 million. Meanwhile, Vanguard Capital Management LLC added 1,197,055 shares to hold a total of 1,197,055 shares worth about $86.1 million.
Analysts Set New Price Targets
Analysts have been maintaining their ratings on NKTR. On May 11, 2026, Wedbush maintained a 'hold' rating with a target price of $80. Piper Sandler kept a 'buy' rating with a target of $192 on May 8. Citigroup also maintained a 'buy' rating, setting a target price of $151 on April 21. Overall, the consensus among analysts indicates a positive outlook, with a mean target price suggesting upside potential.
About NKTR
NKTR is a biopharmaceutical company specializing in the development of innovative therapies to treat chronic pain, cancer, and autoimmune diseases. The company is based in San Francisco, California, and is led by CEO Howard Robin. NKTR is known for its proprietary PEGylation technology, which enhances the pharmacokinetics of drugs, improving their efficacy and safety profiles.
Bottom Line
Howard Robin's recent sale of NKTR shares is part of a planned transaction and reflects ongoing insider activity. Investors often watch such transactions closely for insights into executive sentiment. While insider sales can raise questions, they are not necessarily indicative of future performance. NKTR continues to attract attention from institutional investors and analysts, with many maintaining positive ratings and price targets.
Related Filing Alerts
Source: Howard Robin's Form 4 filing on $NKTR (Jun 17, 2026). Find the original filing: NKTR Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts